Nontuberculous Mycobacterial Infection Market Insights 2025-2034: Growth Dynamics, Trends, and Strategic Opportunities
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What are the Key Projections for the CAGR of the Nontuberculous Mycobacterial Infection Market From 2025 to 2034?
The size of the nontuberculous mycobacterial infection market has experienced robust growth over the past few years. It is set to increase from $14.25 billion in 2024 to $15.11 billion in 2025, with a compound annual growth rate (CAGR) of 6.0%. The historical growth of this market can be tied to enhanced diagnostic procedures, an aging demographic, increased awareness of cystic fibrosis, and the use of immunosuppressive drugs.
In the coming years, the market size for nontuberculous mycobacterial infection is projected to witness substantial growth. Forecasts predict it will expand to $19.57 billion in 2029 with a compound annual growth rate (CAGR) of 6.7%. The expansion during the projected period can be linked to elements such as the development of antimicrobial drugs, increased awareness of ntm, advancements in genetic studies, telehealth and remote examination. The prime trends for the projected period comprise personalized therapy, emphasis on regulations, combined therapies and digital health apparatus.
What Key Drivers Are Accelerating the Growth of the Nontuberculous Mycobacterial Infection Market During the Forecast Period?
The escalating incidence of chronic obstructive pulmonary disease (COPD) is predicted to spur the expansion of the nontuberculous mycobacterial infection market. COPD is a long-term respiratory ailment marked by continuous and often worsening airflow obstruction in the lungs. Patients with COPD suffering from nontuberculous mycobacterial (NTM) infections encounter a more considerable decrease in forced expiratory volume in one second (FEV1) and a higher rate of exacerbation. COPD can compromise the immune system and harm lung tissue, making it more susceptible to NTM bacterial infections. For instance, according to a report issued by The Scottish Public Health Observatory (ScotPHO) in March 2023, COPD rates started to escalate from 2021 to 2022. The rate for men rose from 83.2 to 97.6 per 100,000 individuals, while for women, the rate increased from 72.6 to 97.3. Thus, the escalating prevalence of COPD is propelling the expansion of the nontuberculous mycobacterial infection market. A rise in the prevalence of infectious diseases is projected to boost the nontuberculous mycobacterial infection market’s growth. Infectious diseases, triggered by pathogenic microorganisms like bacteria, viruses, fungi, or parasites, can spread from one person to another, causing various symptoms and health concerns. The growing prevalence of infectious diseases, including conditions that can result in Nontuberculous Mycobacterial (NTM) infections, can potentially drive the nontuberculous mycobacterial infection market’s growth, by promoting awareness about these infections. This can lead to more widespread diagnostic testing and early detection, heightened research and development concerning NTM therapies, and increased demand for treatments targeting NTM pathogens due to a more significant healthcare focus on infectious diseases. For example, in November 2024, according to the United Nations International Children’s Emergency Fund (UNICEF), pneumonia was identified as the most prevalent infectious disease, causing over 700,000 children’s deaths every year, approximately 2,000 children daily. Hence, the growing prevalence of infectious diseases propels the nontuberculous mycobacterial infection market’s growth.
Request Your Free Nontuberculous Mycobacterial Infection Market Report Sample Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=13020&type=smp
What Are the Key Industry Players Leading the Charge in the Nontuberculous Mycobacterial Infection Market’s Growth?
Major companies operating in the nontuberculous mycobacterial infection market are Pfizer Inc., Johnson & Johnson, F. Hoffman La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Eli Lilly and Company, C.H. Boehringer Sohn AG & Co. KG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Vertex Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Horizon Therapeutics PLC, Lupin Limited, BioMarin Pharmaceutical Inc., Ionis Pharmaceuticals Inc., Insmed Incorporated, Paratek Pharmaceuticals Inc., Spero Therapeutics Inc., Aradigm Corporation, Dauntless Pharmaceuticals Inc., Validus Pharmaceuticals LLC.
How Are Market Trends and Shifts Impacting the Growth Trajectory of the Nontuberculous Mycobacterial Infection Market?
Primary businesses in the nontuberculous mycobacterial infection market are embracing innovative treatment approval methods, including fast track designation for pharmaceutical approval, to maintain their market dominance. The FDA’s Fast Track designation is a procedure aimed at rapidly advancing the development and assessment of medications for serious health conditions that lack sufficient medical solutions. For example, the US-based federal entity, the Food and Drug Administration, awarded NUZYRA Fast Track Designation in July 2022 for treating (NTM) lung disease provoked by Mycobacterium avium complex (MAC). NUZYRA (omadacycline), a new broad-spectrum antibiotic, was created to fight against severe bacterial infections, including those brought about by resistant strains. This designation accelerates the development and review processes for the NUZYRA antibiotic to address significant unmet medical demands.
Pre-order Your Report for Quick and Easy Delivery!
How Are the Key Segments of the Nontuberculous Mycobacterial Infection Market Driving Opportunities and Innovations?
The nontuberculous mycobacterial infection market covered in this report is segmented –
1) By Drug Class: Macrolides, Rifampin, Aminoglycoside, Other Drug Classes
2) By Route Of Administration: Oral, Parenteral, Other Routes
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Macrolides: Azithromycin, Clarithromycin
2) By Rifampin: Rifampin, Rifabutin
3) By Aminoglycoside: Amikacin, Streptomycin
4) By Other Drug Classes: Ethambutol, Clofazimine, Linezolid
What Regions Are Influencing the Dynamics of the Nontuberculous Mycobacterial Infection Market?
North America was the largest region in the nontuberculous mycobacterial infection market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in nontuberculous mycobacterial infection market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
How Is the Scope and Reach of the Nontuberculous Mycobacterial Infection Market Defined?
A nontuberculous mycobacterial (NTM) infection is an infectious disease caused by various species of mycobacteria other than mycobacterium tuberculosis, which is responsible for tuberculosis (TB). The role of nontuberculous mycobacterial (NTM) infections is primarily related to their impact on human health and their interaction with the immune system.
Browse Through More Similar Reports By The Business Research Company:
Cough And Cold Preparations Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/cough-and-cold-preparations-global-market-report
Respiratory Disposables Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/respiratory-disposables-global-market-report
Respiratory Monitoring Devices Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: